Cargando…
FDA Approved Drug Library Screening Identifies Robenidine as a Repositionable Antifungal
Due to the increasing prevalence of pathogenic fungal infections, the emergence of antifungal resistant clinical isolates worldwide, and the limited arsenal of available antifungals, developing new antifungal strategies is imperative. In this study, we screened a library of 1068 FDA-approved drugs t...
Autores principales: | Mei, Yikun, Jiang, Tong, Zou, Yun, Wang, Yuanyuan, Zhou, Jia, Li, Jinyang, Liu, Lin, Tan, Jingcong, Wei, Luqi, Li, Jingquan, Dai, Huanqin, Peng, Yibing, Zhang, Lixin, Lopez-Ribot, Jose L., Shapiro, Rebecca S., Chen, Changbin, Liu, Ning-Ning, Wang, Hui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7283467/ https://www.ncbi.nlm.nih.gov/pubmed/32582050 http://dx.doi.org/10.3389/fmicb.2020.00996 |
Ejemplares similares
-
Repurposing the FDA‐approved anticancer agent ponatinib as a fluconazole potentiator by suppression of multidrug efflux and Pma1 expression in a broad spectrum of yeast species
por: Liu, Lin, et al.
Publicado: (2021) -
Repositionable Compounds with Antifungal Activity against Multidrug Resistant Candida auris Identified in the Medicines for Malaria Venture’s Pathogen Box
por: Wall, Gina, et al.
Publicado: (2019) -
Activity Profile of an FDA-Approved Compound Library against Schistosoma mansoni
por: Panic, Gordana, et al.
Publicado: (2015) -
Screening of an FDA-Approved Library for Novel Drugs against Y. pestis
por: Gur, David, et al.
Publicado: (2021) -
Screening and Identification of Lassa Virus Entry Inhibitors from an FDA-Approved Drug Library
por: Wang, Peilin, et al.
Publicado: (2018)